AUB ScholarWorks

The AVAIL ME Extension: A multinational Middle Eastern survey of venous thromboembolism risk and prophylaxis

Show simple item record Mokhtari M. Salameh P. Kouchek M. Kashani B.S. Taher A. Waked M.
dc.contributor.editor Jul-2011 2017-10-05T15:37:56Z 2017-10-05T15:37:56Z 2011
dc.identifier 10.1111/j.1538-7836.2011.04336.x
dc.identifier.issn 15387933
dc.description.abstract Background:Venous thromboembolism (VTE) is a major worldwide problem. Objectives:The primary objectives of this survey were to identify patients at risk for VTE, to define the rate of patients receiving appropriate VTE prophylaxis and to examine the frequency of the presence of guidelines and their application. Patients and methods:Ten countries, 101 hospitals and a total of 4983 patients were included in this multinational cross-sectional survey. Standardized case report forms were filled out by trained individuals on one predefined day. Risks were categorized according to the Caprini Risk Assessment Model. Logistic regressions were carried out to assess factors that determined VTE prophylaxis. Results:Of 4983 patients, 3368 (68percent) and 1615 (32percent) were surgical and medical, respectively. Seven hundred and seventy-two (15.5percent) were considered to be at low risk, 1001 (20percent) at moderate risk, 1289 (26percent) at high risk and 1921 (38.5percent) at very high risk for VTE. Of 3575 (72percent) patients who were eligible to receive VTE prophylaxis, 2747 (77percent) received any drug prophylaxis. Among these patients 720-1056 (68percent) and 2027-2519 (80percent) were medical and surgical patients, respectively. The overall compliance with ACCP guidelines was 38percent, being 24percent for medical patients and 44percent for surgical patients. Conclusions: The results of this large multinational survey, although indicating overall improvement in VTE prophylaxis, identify a considerable number of patients who either did not receive any VTE prophylaxis or received it inappropriately. Although more medical patients were at risk for VTE, they were given prophylaxis less frequently than surgical patients. Concordance with VTE prophylaxis guidelines was higher in surgical patients, but overall application of these tools was unacceptably low. © 2011 International Society on Thrombosis and Haemostasis.
dc.format.extent Pages: (1340-1349)
dc.language English
dc.publisher MALDEN
dc.relation.ispartof Publication Name: Journal of Thrombosis and Haemostasis; Publication Year: 2011; Volume: 9; no. 7; Pages: (1340-1349);
dc.source Scopus
dc.title The AVAIL ME Extension: A multinational Middle Eastern survey of venous thromboembolism risk and prophylaxis
dc.type Article
dc.contributor.affiliation Mokhtari, M., Shahid Beheshti University of Medical Sciences, Tehran, Iran
dc.contributor.affiliation Salameh, P., Lebanese University, Faculties of Pharmacy and of Public Health II, Hadath, Lebanon
dc.contributor.affiliation Kouchek, M., Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
dc.contributor.affiliation Kashani, B.S., Masih Daneshvari Hospital, Shahid Beheshti Universiy of Medical Sciences, Tehran, Iran
dc.contributor.affiliation Taher, A., American University of Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Waked, M., Balamand University and St George Hospital, Beirut, Lebanon
dc.contributor.authorAddress Salameh, P.; Jdeidet El Meten, Chalet Suisse Street,Ramza Azzam bldg, 5th floor, Beirut 00961, Lebanon; email:
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Mokhtari, M
dc.contributor.authorInitials Salameh, P
dc.contributor.authorInitials Kouchek, M
dc.contributor.authorInitials Kashani, BS
dc.contributor.authorInitials Taher, A
dc.contributor.authorInitials Waked, M
dc.contributor.authorReprintAddress Salameh, P (reprint author), Chalet Suisse St,Ramza Azzam Bldg,5th Floor, Beirut 00961, Lebanon.
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Ageno W, 2002, CURR HEMATOL REP, V88, P73; ANDERSON FA, 1995, CLIN CHEST MED, V16, P235; ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001-archinte.151.5.933; Arcelus JI, 2003, J VASC SURG, V38, P916, DOI 10.1016-S0741-5214(03)00789-4; Awidi A, 2009, J THROMB THROMBOLYS, V28, P309, DOI 10.1007-s11239-008-0291-1; Bahl V, 2010, ANN SURG, V251, P344, DOI 10.1097-SLA.0b013e3181b7fca6; Baroletti S, 2008, J THROMB THROMBOLYS, V25, P146, DOI 10.1007-s11239-007-0081-1; Birks ME, 2002, PHLEBOLOGY, V16, P121, DOI 10.1007-s005230200007; Byrnes MC, 2009, CRIT CARE MED, V37, P2775, DOI 10.1097-CCM.0b013e3181a96379; Clagett GP, 1998, CHEST S, V114, P531; Cohen AT, 2008, LANCET, V371, P387, DOI 10.1016-S0140-6736(08)60202-0; Cohen A T, 2001, Curr Opin Pulm Med, V7, P332, DOI 10.1097-00063198-200109000-00014; Deheinzelin D, 2006, J THROMB HAEMOST, V4, P1266, DOI 10.1111-j.1538-7836.2006.01981.x; Fletcher J, 1998, MANAGEMENT PREVENTIO; Geerts W, 2003, CHEST, V124, p357S, DOI 10.1378-chest.124.6_suppl.357S; Geerts WH, 2004, CHEST, V126, p338S; Geerts WH, 2001, CHEST S1, V119, P132; Goldhaber SZ, 2004, AM J CARDIOL, V93, P259, DOI 10.1016-j.amjcard.2003.09.057; Golhaber S., 2006, KARDIOVASKULARE MED, V9, P102; Hirsh J, 2008, CHEST, V133, p110S, DOI 10.1378-chest.08-0652; Huang A, 2000, ANN ROY COLL SURG, V82, P69; Kakkar AK, 2010, ANN SURG, V251, P330, DOI [10.1097-SLA.0b013e3181c0e58f, 10.1097-SLA.0b013e3181c0c58f]; Kohn LT, 2000, ERR IS HUMAN BUILDIN; MACKLON N, 1995, THROMBOPROPHYLAXIS O; Maman AFOB, 2006, ANN FR ANESTH, V25, P1107, DOI 10.1016-j.annfar.2006.06.020; Motykie GD, 2000, J THROMB THROMBOLYS, V9, P253, DOI 10.1023-A:1018770712660; Nicolaides AN, 2001, INT ANGIOL, V20, P1; Piazza G, 2007, CHEST, V132, P554, DOI 10.1378-chest.07-0430; Prandoni P, 1997, HAEMATOLOGICA, V82, P423; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097-00005373-200207000-00032; Rothman KJ, 2008, MODERN EPIDEMIOLOGY; Scurr J, 1998, PHLEBOLOGY, V13, P87; Spencer FA, 2007, ARCH INTERN MED, V167, P1471, DOI 10.1001-archinte.167.14.1471; Stein PD, 2005, AM J CARDIOL, V95, P1525, DOI 10.1016-j.amjcard.2005.02.030; Taher AT, 2011, J THROMB THROMBOLYS, V31, P47, DOI 10.1007-s11239-010-0492-2; Warkentin TE, 2007, HEMATOL ONCOL CLIN N, V21, P589, DOI 10.1016-j.hoc.2007.06.004; Zeitoun AA, 2009, J THROMB THROMBOLYS, V28, P192, DOI 10.1007-s11239-008-0298-7
dc.description.citedCount 6
dc.description.citedTotWOSCount 5
dc.description.citedWOSCount 5
dc.format.extentCount 10
dc.identifier.coden JTHOA
dc.identifier.pubmedID 21605327
dc.identifier.scopusID 79959821583
dc.publisher.address COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
dc.relation.ispartOfISOAbbr J. Thromb. Haemost.
dc.relation.ispartOfIssue 7
dc.relation.ispartofPubTitle Journal of Thrombosis and Haemostasis
dc.relation.ispartofPubTitleAbbr J. Thromb. Haemost.
dc.relation.ispartOfVolume 9
dc.source.ID WOS:000292336600009
dc.type.publication Journal
dc.subject.otherAuthKeyword Guidelines
dc.subject.otherAuthKeyword Middle East
dc.subject.otherAuthKeyword Prophylaxis
dc.subject.otherAuthKeyword Risk assessment
dc.subject.otherAuthKeyword Venous thromboembolism
dc.subject.otherChemCAS fondaparinux, 104993-28-4, 114870-03-0
dc.subject.otherChemCAS heparin, 37187-54-5, 8057-48-5, 8065-01-8, 9005-48-5
dc.subject.otherIndex anticoagulant agent
dc.subject.otherIndex antineoplastic agent
dc.subject.otherIndex antivitamin K
dc.subject.otherIndex fondaparinux
dc.subject.otherIndex heparin
dc.subject.otherIndex low molecular weight heparin
dc.subject.otherIndex adult
dc.subject.otherIndex article
dc.subject.otherIndex cancer chemotherapy
dc.subject.otherIndex cancer hormone therapy
dc.subject.otherIndex compression bandage
dc.subject.otherIndex cross-sectional study
dc.subject.otherIndex drug contraindication
dc.subject.otherIndex female
dc.subject.otherIndex high risk patient
dc.subject.otherIndex human
dc.subject.otherIndex major clinical study
dc.subject.otherIndex male
dc.subject.otherIndex patient compliance
dc.subject.otherIndex practice guideline
dc.subject.otherIndex priority journal
dc.subject.otherIndex risk assessment
dc.subject.otherIndex surgical patient
dc.subject.otherIndex treatment contraindication
dc.subject.otherIndex venous thromboembolism
dc.subject.otherIndex Chemoprevention
dc.subject.otherIndex Cross-Sectional Studies
dc.subject.otherIndex Data Collection
dc.subject.otherIndex Guideline Adherence
dc.subject.otherIndex Humans
dc.subject.otherIndex Middle East
dc.subject.otherIndex Postoperative Complications
dc.subject.otherIndex Risk Assessment
dc.subject.otherIndex Risk Factors
dc.subject.otherIndex Venous Thromboembolism
dc.subject.otherKeywordPlus DEEP-VEIN THROMBOSIS
dc.subject.otherKeywordPlus PULMONARY-EMBOLISM
dc.subject.otherKeywordPlus HOSPITALIZED-PATIENTS
dc.subject.otherKeywordPlus PROSPECTIVE REGISTRY
dc.subject.otherKeywordPlus SURGICAL-PATIENTS
dc.subject.otherKeywordPlus SETTING ENDORSE
dc.subject.otherKeywordPlus VTE RISK
dc.subject.otherKeywordPlus PREVENTION
dc.subject.otherKeywordPlus GUIDELINES
dc.subject.otherKeywordPlus MANAGEMENT
dc.subject.otherWOS Hematology
dc.subject.otherWOS Peripheral Vascular Disease

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


My Account